Clinical Trial: Clinical Study of SHR-A1811 Combined With Pertuzumab as Second-Line Therapy in Patients With HER2-Altered Advanced NSCLC

U.S., Jan. 31 -- ClinicalTrials.gov registry received information related to the study (NCT07377916) titled 'Clinical Study of SHR-A1811 Combined With Pertuzumab as Second-Line Therapy in Patients With HER2-Altered Advanced NSCLC' on Dec. 02, 2025.

Brief Summary: The study enrolled patients with advanced or metastatic NSCLC harboring HER2 mutations, amplification, or overexpression who had progressed after >=1 prior lines of anticancer therapy. After enrollment, participants received treatment with rezetamab plus pertuzumab until disease progression, intolerable toxicity, withdrawal of consent, or other conditions requiring treatment discontinuation.

Study Start Date: Feb. 15

Study Type: INTERVENTIONAL

Condition: Non-Small Cell Lung Ca...